Sanofi and GlaxoSmithKline plan to supply 200 million doses of their experimental coronavirus vaccine to the investment facility for COVAX, an international group working to equitably distribute COVID-19 treatments around the globe.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,